Advertisement

© 2011

Drug Product Development for the Back of the Eye

  • Uday B. Kompella
  • Henry F. Edelhauser
  • Written by top investigators in respective areas

  • Addresses methods of tissue isolation and drug analysis, noninvasive approaches and nanotechnology based products

  • Presents approaches to assess and model pharmacokinetics of the eye noninvasively as well as a comprehensive coverage of transscleral drug delivery

Book

Part of the AAPS Advances in the Pharmaceutical Sciences Series book series (AAPS, volume 2)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Ravi D. Vaishya, Hari Krishna Ananthula, Ashim K. Mitra
    Pages 21-45
  3. Bernard E. McCarey
    Pages 47-84
  4. Masanori Tachikawa, Vadivel Ganapathy, Ken-ichi Hosoya
    Pages 85-109
  5. Thomas Gadek, Dennis Lee
    Pages 111-124
  6. Clive G. Wilson, Lay Ean Tan, Jenifer Mains
    Pages 125-158
  7. Dayle H. Geroski, Henry F. Edelhauser
    Pages 159-171
  8. Timothy W. Olsen, Brian C. Gilger
    Pages 173-184
  9. Susan S. Lee, Patrick Hughes, Aron D. Ross, Michael R. Robinson
    Pages 185-230
  10. Shelley A. Durazo, Uday B. Kompella
    Pages 261-290
  11. Gauri P. Misra, Thomas W. Gardner, Tao L. Lowe
    Pages 291-304
  12. Samirkumar R. Patel, Henry F. Edelhauser, Mark R. Prausnitz
    Pages 331-360
  13. Francine F. Behar-Cohen, Peter Milne, Jean-Marie Parel, Indu Persaud
    Pages 361-390
  14. John M. Nickerson, Jeffrey H. Boatright
    Pages 391-408
  15. Rinku Baid, Puneet Tyagi, Shelley A. Durazo, Uday B. Kompella
    Pages 409-448
  16. Jithan Aukunuru, Puneet Tyagi, Chandrasekar Durairaj, Uday B. Kompella
    Pages 449-468

About this book

Introduction

This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs. Specific topics covered in this book include:

  • Solution, suspension, gel, nanoparticle, microparticle, and implant dosage forms
  • Refillable and microneedle devices
  • Intravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of delivery
  • Physical methods including iontophoresis for drug delivery
  • Rational selection of routes of administration and delivery systems
  • Noninvasive and continuous drug monitoring
  • Clinical endpoints and regulatory path to drug product development
  • Emerging and existing drugs and drug targets

 

Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering.

 

Uday B. Kompella, Ph.D., Professor of Pharmaceutical Sciences & Ophthalmology, University of Colorado, developed functionalized nanoparticles, nanoporous microparticles, microparticles, injectable implants, dendrimers, liposomes, and in situ forming gels for the eye. He is a Fellow of the American Association of Pharmaceutical Scientists (2005) and the Association for Research in Vision and Ophthalmology (2010). He received Distinguished Scientist (2006) Award from the University of Nebraska.

 

Henry F. Edelhauser, Ph.D., Professor of Ophthalmology, Emory University, made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. He is a recipient of the Castroviejo Medal and the Alcon Research Award (1999), American Academy of Ophthalmology Senior Achievement Award (2000), and the Procter Medal (2005) for his outstanding ophthalmic translational research. He served as the president of the Association for Research in Vision and Ophthalmology (1990-91).

Keywords

AAPS Back Development Drug Edelhauser Eye Kompella Product

Editors and affiliations

  • Uday B. Kompella
    • 1
  • Henry F. Edelhauser
    • 2
  1. 1.School of PharmacyUniversity of Colorado DenverAuroraUSA
  2. 2.School of MedicineEmory UniversityAtlantaUSA

About the editors

Uday B. Kompella, Ph.D. has been an independent faculty member in the field of drug delivery for 17 years, with ocular drug delivery being a key research focus. Prior to joining University of Colorado in 2008, he served as a faculty member at University of Nebraska for 10 years and at Auburn University for 4 years. Dr. Kompella’s research, published in over 100 peer-reviewed articles, is focused on developing new drug and gene delivery approaches for treating neovascular diseases including diabetic retinopathy, age-related macular degeneration, and cancer. Dr. Kompella developed and assessed several drug delivery systems including functionalized nanoparticles, nanoporous microparticles, microparticles, injectable implants, dendrimers, liposomes, and in situ forming gels for ophthalmic applications. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (2005) and the Association for Research in Vision and Ophthalmology (2010). He was recognized as a Distinguished Scientist in 2006 and as a Distinguished Teacher in 2003 at University of Nebraska Medical Center.

Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications.

Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications.

Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications.

Bibliographic information

Industry Sectors
Biomedicine
Pharma
Health & Hospitals
Biotechnology
Pharmacology & Toxicology
Law
Consumer Packaged Goods